CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
doxorubicin HCL liposome; bevacizumab; carboplatindrug
Likely dose
doxorubicin HCL liposome; bevacizumab; carboplatin 30 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00698451
NCT00698451Phase 2Completed
CompareCT.gov

A Phase II Single Arm Study of Carboplatin and DOXIL (PLD) Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Jun 17, 2008·Updated Sep 6, 2013

In Brief

A Phase 2 clinical trial evaluating doxorubicin HCL liposome; bevacizumab; carboplatin for Ovarian Neoplasms and 2 related conditions. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the response rate (Complete Response (CR) and Partial Response (PR)) to carboplatin and DOXIL treatment in combination with bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube and primary peritoneal cancers. All patients will received DOXIL, carboplatin and bevacizumab for a maximum of ten 28-day cycles. Patients will be followed for six months following treatment to assess progression-free survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
CountriesUnited States
CollaboratorsCentocor Ortho Biotech Services, L.L.C.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 17, 2008
Enrollment StartAug 1, 2008
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 18.0 years ago

Interventions

doxorubicin HCL liposome; bevacizumab; carboplatindrug

30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle